Finally, A Foundational Heart Failure Drug That Works Across the Spectrum of EF
BARCELONA — With a major win in DELIVER, dapagliflozin (Farxiga) closed the gap on the types of heart failure (HF) proven to be treated safely by SGLT2 inhibition. People with HF with preserved (HFpEF) and mildly reduced ejection fraction (HFmrEF) alike had a reduced risk of cardiovascular (CV) death and worsening HF over a median […]